Key 2015 Milestones are Partnering of AmiKet and Phase II Data for Bertilimumab in Bullous Pemphigoid

Report Available here: www.lifescicapital.com/equity-research/immune/

NEW YORK, NY / ACCESSWIRE / February 3, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Immune Pharmaceuticals (NasdaqCM: IMNP), utilizes a personalized, bio-marker based approach to treating inflammatory diseases and cancer through the development of novel, targeted antibody therapeutics. Immune's clinical candidate bertilimumab targets eotaxin-1, a mediator of inflammation. The candidate is in Phase II trials for ulcerative colitis and bullous pemphigoid, with data expected in late 2015 for BP and the first half 2016 for UC. Immune is also developing AmiKet, a topical analgesic cream for the treatment of neuropathic pain associated with permanent damage to the peripheral nervous system.

AmiKet is a combination of two FDA-approved drugs, amitriptyline and ketamine, that has been extensively tested in over 1,600 patients in Phase II clinical trials. Peripheral neuropathy has a variety of causes including diabetes, chemotherapy, and bacterial or viral infections, and Immune has evaluated AmiKet in Phase II trials for several forms of neuropathic pain. The Company has chosen postherpetic neuralgia as its lead program for AmiKet and has received orphan drug designation for this indication. Immune Pharmaceuticals is seeking a partner to bring this program into Phase III testing and eventually to help with commercialization and marketing.

In a 34 page Initiation Report LifeSci Capital explains the development pathway for bertilimumab in ulcerative colitis, bullous pemphigoid, and related conditions. The report highlights the scientific rationale behind using bertilimumab and the competitive landscape in these indications, and explores the market potential for bertilimumab and AmiKet.

Dr. Isaacson's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Immune Pharmaceuticals as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com


SOURCE: LifeSci Capital, LLC